No Data
Yiming Pharmaceutical: 2024 Annual Performance Forecast
Tibet Aim Pharm. Inc. (002826.SZ): Cooperation with SH PHARMA's subsidiary on the third-party product cucumber skin injection solution has been terminated.
On December 24, Glonghui reported that Tibet Aim Pharm. Inc. (002826.SZ) announced that the third-party cooperative product, Trichosanthes Fruit Skin Injection (Xintong), is a variety operated in cooperation with a subsidiary of SH PHARMA. Currently, after full consultation with SH PHARMA, the company has decided to terminate the cooperation, and the agreement will not be renewed after December 2024. According to preliminary calculations by the finance department, the revenue generated by this product in 2024 is expected to be 85 million yuan, accounting for more than 10% of the company's most recent audited revenue. According to the regulations of the "Shenzhen Stock Exchange Listing Rules" and relevant laws and regulations, this matter meets the...
Tibet Aim Pharm. Inc. (002826.SZ) plans to promote a restricted stock incentive plan for 4.86 million shares.
Tibet Aim Pharm. Inc. (002826.SZ) disclosed the draft of the 2024 restricted stock incentive plan, which intends to grant incentives...
Tibet aim pharm. inc. (002826.SZ) has appointed Cui Jingsheng and Yang Lian as deputy general managers.
tibet aim pharm. inc. (002826.SZ) announced that the company has been strengthening its talent team building in recent years, focusing on internal...
Yiming Pharmaceutical: Report for the third quarter of 2024
tibet aim pharm. inc. (002826.SZ) released its performance for the first three quarters, with a net income of 41.8194 million yuan, a year-on-year increase of 75.06%.
tibet aim pharm. inc. (002826.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved revenue...